On Tuesday, Myriad Genetics (NASDAQ: MYGN) will release its latest earnings report. Benzinga's outlook for Myriad Genetics is included in the following report.
Earnings and Revenue
Based on management's projections, Myriad Genetics analysts model for earnings of 24 cents per share on sales of $188.87 million.
Myriad Genetics reported a profit of 26 cents per share when it published results during the same quarter last year. Sales in that period totaled $196 million. If the company were to report inline earnings when it publishes results Tuesday, sales would be down 3.88 percent from the same quarter last year. Myriad Genetics's reported EPS has stacked up against analyst estimates in the past like this:
|Quarter||Q1 2018||Q4 2017||Q3 2017||Q2 2017|
Q2 EPS Estimate: 24 cents per share
Q2 Revenues Estimate: $188 million
Shares of Myriad Genetics were trading around $36.16. Over the last 52-week period, shares are up 127.28 percent. Given that these returns are generally positive, long-term shareholders can be content going into this earnings release.
Analyst estimates have adjusted lower for EPS and revenues over the past 90 days. The average rating by analysts on Myriad Genetics stock is a Sell. The validity of this rating has maintained conviction over the past 90 days.
Myriad Genetics's Q2 is scheduled to hold a conference call at 4:30 p.m. ET.
See more from Benzinga
- Earnings Outlook For Gilead Sciences
- Chipotle Mexican Grill's Q4 Earnings Preview
- Anadarko Petroleum Earnings Preview
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.